Home  »  Companies   »  I-Mab (IMAB) Is A Stock Worth Accumulating At Curr...

I-Mab (IMAB) Is A Stock Worth Accumulating At Current Levels

I-Mab (NASDAQ:IMAB) concluded the trading at $3.70 on Wednesday, November 23 with a rise of 1.09% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $3.66 and 5Y monthly beta was reading 0.99. Considering stock’s 52-week price range provides that IMAB hit a high price of $67.84 and saw its price falling to a low level of $3.25 during that period. Over a period of past 1-month, stock came subtracting -1.86% in its value.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


With its current market valuation of $312.72 million, I-Mab is set to declare its quarterly results on Aug 30, 2022. Analysts are in estimates of $0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0 for 2020 with estimates of that growing to $0 in next year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review IMAB stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

Digging deeper we become aware of the PEG ratio of the IMAB stock which is currently positioned at 0. It further provides that stock’s current price level is -6.70% away from its 20-day simple moving average and is -9.73% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 43.38 while volatility remained at 5.99% over the past week which changes to 7.62% when measuring it over the past month. Average true range or ATR is currently at 0.31. In predicting price targets of as low as $3.80 and as high as $64.60, analysts are in agreement on assigning the stock over the next 12 months average price target of $32.77. Stock’s current price level is -2.7% above from estimated low price target while it is -1645.95% below the estimated high; and even if the IMAB’s share succeeded to reach the median price of $32.67, then the outlook of -782.97% could come to the excitement of the investors.

In comparing I-Mab (IMAB)’s stock with other industry players reveals that stock’s current price change of 1.09% and that of -94.25% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price raised by 0.11% in the last trading and went through an increase of 10.16% in past 12-month trading. Industry’s another major player Eli Lilly and Company (LLY) has rise 0.23% up in previous session, but over the past year has faced a rise of 38.08%, while AbbVie Inc. (ABBV) was also down -0.25% however its price remained floating in the green at 34.08% over the same period. I-Mab has a P/E ratio of 0 against that of Johnson & Johnson’s 24.64 while Eli Lilly and Company is showing 54.36 for the same. On the other hand, the S&P 500 Index was up 0.59% in the last trading session while the Dow Jones Industrial closed the session higher at 0.28%.

Having a second look at I-Mab (NASDAQ:IMAB) provides that stock’s average daily trading volume for 3 months was 544.22K, while it jumped to 0.38 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 82.11 million.

The percentage of outstanding shares held by the insiders is 1.30% while it is 50.90% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 2.2 million which implies a short ratio of 3.41. This shows down a 2.64% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 2.61 million in the previous month. Subtraction of -92.19% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *